Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemours (CC) Asset Writedowns and Impairment (2016)

Chemours (CC) has 2 years of Asset Writedowns and Impairment data on record, last reported at $46.0 million in Q3 2016.

  • For Q3 2016, Asset Writedowns and Impairment rose 2.22% year-over-year to $46.0 million; the TTM value through Sep 2016 reached $149.0 million, changed N/A, while the annual FY2015 figure was $48.0 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $46.0 million in Q3 2016 per CC's latest filing, down from $58.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $58.0 million in Q2 2016 and bottomed at $45.0 million in Q3 2015.